ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för PJ34. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

44 träffar

Bibliografisk träff 2021-03-26

Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2.

Zhao D, Xu W, Zhang X, Wang X, Ge Y, Yuan E, Xiong Y, Wu S, Li S, Wu N, Tian T, Feng X, Shu H, Lang P, Li J, Zhu F, Shen X, Li H, Li P, Zeng J.

Protein Cell · letter; comment; research support, non-u.s. gov't · DOI 10.1007/s13238-021-00832-z

Bibliografisk träff 2021-02-26

PJ34, a PARP1 inhibitor, attenuates acute allograft rejection after murine heart transplantation via regulating the CD4+ T lymphocyte response.

Chen X, Huang Y, Wang D, Dong N, Du X.

Transpl Int · research support, non-u.s. gov't; journal article · DOI 10.1111/tri.13809

Bibliografisk träff 2021-01-20

Inhibition of PARP activity improves therapeutic effect of ARPE-19 transplantation in RCS rats through decreasing photoreceptor death.

Gao F, Li Z, Kang Z, Liu D, Li P, Ou Q, Xu JY, Li W, Tian H, Jin C, Wang J, Zhang J, Zhang J, Lu L, Xu GT.

Exp Eye Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.exer.2021.108448

Bibliografisk träff 2020-09-08

Cerebral Vasodilator Property of Poly(ADP-Ribose) Polymerase Inhibitor (PJ34) in the Neonatal and Adult Mouse Is Mediated by the Nitric Oxide Pathway.

Bonnin P, Charriaut-Marlangue C, Pansiot J, Boutigny A, Launay JM, Besson VC.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms21186569

Bibliografisk träff 2020-06-19

The Modified Phenanthridine PJ34 Unveils an Exclusive Cell-Death Mechanism in Human Cancer Cells.

Cohen-Armon M.

Cancers (Basel) · review-article; review; journal article · DOI 10.3390/cancers12061628

Bibliografisk träff 2020-06-15

PJ34 Protects Photoreceptors from Cell Death by Inhibiting PARP-1 Induced Parthanatos after Experimental Retinal Detachment.

Dong K, Yan Y, Lu L, Wang Y, Li J, Zhang M, Ding J.

Curr Eye Res · research support, non-u.s. gov't; journal article · DOI 10.1080/02713683.2020.1776881

Bibliografisk träff 2020-02-04

Correction: The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts.

Visochek L, Atias D, Spektor I, Castiel A, Golan T, Cohen-Armon M.

Oncotarget · published erratum; correction · DOI 10.18632/oncotarget.27440

Bibliografisk träff 2019-10-22

The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts.

Visochek L, Atias D, Spektor I, Castiel A, Golan T, Cohen-Armon M.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.27268

Bibliografisk träff 2019-10-01

Treatment with the poly(ADP-ribose) polymerase inhibitor PJ-34 improves cerebromicrovascular endothelial function, neurovascular coupling responses and cognitive performance in aged mice, supporting the NAD+ depletion hypothesis of neurovascular aging.

Tarantini S, Yabluchanskiy A, Csipo T, Fulop G, Kiss T, Balasubramanian P, DelFavero J, Ahire C, Ungvari A, Nyúl-Tóth Á, Farkas E, Benyo Z, Tóth A, Csiszar A, Ungvari Z.

Geroscience · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1007/s11357-019-00101-2

Bibliografisk träff 2019-07-15

PJ34, a PARP1 inhibitor, promotes endothelial repair in a rabbit model of high fat diet-induced atherosclerosis.

Zha S, Wang F, Li Z, Ma Z, Yang L, Liu F.

Cell Cycle · research support, non-u.s. gov't; research-article; journal article · DOI 10.1080/15384101.2019.1640008

Bibliografisk träff 2019-05-07

PARP Inhibitor PJ34 Protects Mitochondria and Induces DNA-Damage Mediated Apoptosis in Combination With Cisplatin or Temozolomide in B16F10 Melanoma Cells.

Cseh AM, Fabian Z, Quintana-Cabrera R, Szabo A, Eros K, Soriano ME, Gallyas F, Scorrano L, Sumegi B.

Front Physiol · research-article; journal article · DOI 10.3389/fphys.2019.00538

Bibliografisk träff 2019-01-25

Deimmunizing substitutions in Pseudomonas exotoxin domain III perturb antigen processing without eliminating T-cell epitopes.

Moss DL, Park HW, Mettu RR, Landry SJ.

J Biol Chem · research-article; journal article; research support, n.i.h., extramural · DOI 10.1074/jbc.ra118.006704

Bibliografisk träff 2019-01-18

Suppression of cell cycle progression by poly(ADP-ribose) polymerase inhibitor PJ34 in neural stem/progenitor cells.

Kurokawa S, Okuda A, Nishizawa Y, Furukawa K, Sumihiro A, Nakaji Y, Tanaka S, Takehashi M.

Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2019.01.025

Bibliografisk träff 2018-08-23

PARP1 inhibitor (PJ34) improves the function of aging-induced endothelial progenitor cells by preserving intracellular NAD+ levels and increasing SIRT1 activity.

Zha S, Li Z, Cao Q, Wang F, Liu F.

Stem Cell Res Ther · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s13287-018-0961-7

Bibliografisk träff 2018-04-12

Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice.

El Amki M, Lerouet D, Garraud M, Teng F, Beray-Berthat V, Coqueran B, Barsacq B, Abbou C, Palmier B, Marchand-Leroux C, Margaill I.

Mol Neurobiol · journal article · DOI 10.1007/s12035-018-1063-3

Bibliografisk träff 2018-01-09

Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Attenuated Hepatic Triglyceride Accumulation in Alcoholic Fatty Liver Disease in Mice.

Huang S, Zhang B, Chen Y, Liu H, Liu Y, Li X, Bao Z, Song Z, Wang Z.

J Pharmacol Exp Ther · research support, non-u.s. gov't; journal article · DOI 10.1124/jpet.117.243105

Bibliografisk träff 2017-05-01

Cytotoxicity of anticancer drugs and PJ-34 (poly(ADP-ribose)polymerase-1 (PARP-1) inhibitor) on HL-60 and Jurkat cells.

Stępnik M, Spryszyńska S, Gorzkiewicz A, Ferlińska M.

Adv Clin Exp Med · journal article · DOI 10.17219/acem/60848

Bibliografisk träff 2016-12-21

Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.

Thorsell AG, Ekblad T, Karlberg T, Löw M, Pinto AF, Trésaugues L, Moche M, Cohen MS, Schüler H.

J Med Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.jmedchem.6b00990

Bibliografisk träff 2016-07-05

The PARP inhibitor PJ-34 sensitizes cells to UVA-induced phototoxicity by a PARP independent mechanism.

Lakatos P, Hegedűs C, Salazar Ayestarán N, Juarranz Á, Kövér KE, Szabó É, Virág L.

Mutat Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.mrfmmm.2016.07.001

Bibliografisk träff 2016-03-21

Scabin, a Novel DNA-acting ADP-ribosyltransferase from Streptomyces scabies.

Lyons B, Ravulapalli R, Lanoue J, Lugo MR, Dutta D, Carlin S, Merrill AR.

J Biol Chem · research support, non-u.s. gov't; research-article; journal article · DOI 10.1074/jbc.m115.707653

Bibliografisk träff 2015-10-23

Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells.

Bai XT, Moles R, Chaib-Mezrag H, Nicot C.

J Hematol Oncol · research-article; journal article; research support, n.i.h., extramural · DOI 10.1186/s13045-015-0217-2

Bibliografisk träff 2015-04-28

PJ-34 inhibits PARP-1 expression and ERK phosphorylation in glioma-conditioned brain microvascular endothelial cells.

Motta C, D'Angeli F, Scalia M, Satriano C, Barbagallo D, Naletova I, Anfuso CD, Lupo G, Spina-Purrello V.

Eur J Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejphar.2015.04.026

Bibliografisk träff 2015-01-29

Structural basis for lack of ADP-ribosyltransferase activity in poly(ADP-ribose) polymerase-13/zinc finger antiviral protein.

Karlberg T, Klepsch M, Thorsell AG, Andersson CD, Linusson A, Schüler H.

J Biol Chem · research support, non-u.s. gov't; research-article; journal article · DOI 10.1074/jbc.m114.630160

Bibliografisk träff 2014-10-15

Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia.

Greco R, Tassorelli C, Mangione AS, Levandis G, Certo M, Nappi G, Bagetta G, Blandini F, Amantea D.

Eur J Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejphar.2014.10.006

Bibliografisk träff 2014-09-27

Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.

Qiu W, Lam R, Voytyuk O, Romanov V, Gordon R, Gebremeskel S, Vodsedalek J, Thompson C, Beletskaya I, Battaile KP, Pai EF, Rottapel R, Chirgadze NY.

Acta Crystallogr D Biol Crystallogr · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1107/s1399004714017660

Bibliografisk träff 2014-03-12

Structural basis for the identification of the N-terminal domain of coronavirus nucleocapsid protein as an antiviral target.

Lin SY, Liu CL, Chang YM, Zhao J, Perlman S, Hou MH.

J Med Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/jm500089r

Bibliografisk träff 2013-11-20

Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors.

Haikarainen T, Narwal M, Joensuu P, Lehtiö L.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/ml400292s

Bibliografisk träff 2013-08-21

Cell death associated with abnormal mitosis observed by confocal imaging in live cancer cells.

Castiel A, Visochek L, Mittelman L, Zilberstein Y, Dantzer F, Izraeli S, Cohen-Armon M.

J Vis Exp · video-audio media; research support, non-u.s. gov't; research-article; journal article · DOI 10.3791/50568

Bibliografisk träff 2012-09-26

PARP-1 inhibitors DPQ and PJ-34 negatively modulate proinflammatory commitment of human glioblastoma cells.

Scalia M, Satriano C, Greca R, Stella AM, Rizzarelli E, Spina-Purrello V.

Neurochem Res · research support, non-u.s. gov't; journal article · DOI 10.1007/s11064-012-0887-x

Bibliografisk träff 2012-09-17

Administration of poly(ADP-ribose) polymerase inhibitor into bronchial artery attenuates pulmonary pathophysiology after smoke inhalation and burn in an ovine model.

Hamahata A, Enkhbaatar P, Lange M, Yamaki T, Sakurai H, Shimoda K, Nakazawa H, Traber LD, Traber DL.

Burns · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1016/j.burns.2012.08.021

Gå till forskningen.

Publikationer i urvalet

Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2.

PJ34, a PARP1 inhibitor, attenuates acute allograft rejection after murine heart transplantation via regulating the CD4<sup>+</sup> T lymphocyte response.

Inhibition of PARP activity improves therapeutic effect of ARPE-19 transplantation in RCS rats through decreasing photoreceptor death.

Cerebral Vasodilator Property of Poly(ADP-Ribose) Polymerase Inhibitor (PJ34) in the Neonatal and Adult Mouse Is Mediated by the Nitric Oxide Pathway.

The Modified Phenanthridine PJ34 Unveils an Exclusive Cell-Death Mechanism in Human Cancer Cells.

PJ34 Protects Photoreceptors from Cell Death by Inhibiting PARP-1 Induced Parthanatos after Experimental Retinal Detachment.

Correction: The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts.

The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts.

Treatment with the poly(ADP-ribose) polymerase inhibitor PJ-34 improves cerebromicrovascular endothelial function, neurovascular coupling responses and cognitive performance in aged mice, supporting the NAD+ depletion hypothesis of neurovascular aging.

PJ34, a PARP1 inhibitor, promotes endothelial repair in a rabbit model of high fat diet-induced atherosclerosis.

PARP Inhibitor PJ34 Protects Mitochondria and Induces DNA-Damage Mediated Apoptosis in Combination With Cisplatin or Temozolomide in B16F10 Melanoma Cells.

Deimmunizing substitutions in <i>Pseudomonas</i> exotoxin domain III perturb antigen processing without eliminating T-cell epitopes.

Suppression of cell cycle progression by poly(ADP-ribose) polymerase inhibitor PJ34 in neural stem/progenitor cells.

PARP1 inhibitor (PJ34) improves the function of aging-induced endothelial progenitor cells by preserving intracellular NAD<sup>+</sup> levels and increasing SIRT1 activity.

Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice.

Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Attenuated Hepatic Triglyceride Accumulation in Alcoholic Fatty Liver Disease in Mice.

Cytotoxicity of anticancer drugs and PJ-34 (poly(ADP-ribose)polymerase-1 (PARP-1) inhibitor) on HL-60 and Jurkat cells.

Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.

The PARP inhibitor PJ-34 sensitizes cells to UVA-induced phototoxicity by a PARP independent mechanism.

Scabin, a Novel DNA-acting ADP-ribosyltransferase from Streptomyces scabies.

Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells.

PJ-34 inhibits PARP-1 expression and ERK phosphorylation in glioma-conditioned brain microvascular endothelial cells.

Structural basis for lack of ADP-ribosyltransferase activity in poly(ADP-ribose) polymerase-13/zinc finger antiviral protein.

Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia.

Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.

Structural basis for the identification of the N-terminal domain of coronavirus nucleocapsid protein as an antiviral target.

Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors.

Cell death associated with abnormal mitosis observed by confocal imaging in live cancer cells.

PARP-1 inhibitors DPQ and PJ-34 negatively modulate proinflammatory commitment of human glioblastoma cells.

Administration of poly(ADP-ribose) polymerase inhibitor into bronchial artery attenuates pulmonary pathophysiology after smoke inhalation and burn in an ovine model.